You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
DxTerity aims to develop a genomic blood test to identify which cancer patients are most likely to benefit from radiation therapy or are at risk for toxicity.
Alere is divesting Epocal as it seeks regulatory approval of its merger with Abbott. Based in Ottawa, Ontario, Epocal develops point-of-care blood diagnostic systems.
The deal with Viagene is for Streck's cell stabilization products, while the agreement with Medico also includes Streck's molecular products.
An OpenArray panel designed to simultaneously test for 17 viruses and 13 bacteria and protozoa was able to detect pathogens from human blood donor samples with an accuracy of about 95 percent.
The updated Class I recall now includes Magellan Diagnostics' LeadCare and LeadCare II Blood Lead Testing Systems, all serial and lot numbers.
The fully-automated system features technology to measure blood volumes in each culture bottle to ensure compliance with accreditation guidelines.
Research using the T2Plex instrument has detected a new conformation of red blood cells indicating a tight clot, which could be used as a biomarker.
The NSF and NIH awarded the firm separate grants to develop the system, which can provide results in five minutes from a drop of blood.
The test can now be used to detect EGFR mutations in tissue and blood for lung cancer patients considering treatment with the tyrosine kinase inhibiting drugs Tarceva and Tagrisso.
The new guidance could benefit Hologic and Roche, both of which market molecular blood screening tests authorized by the FDA under an investigational new drug study protocol.